MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, URGN made $27,482,000 in revenue. -$33,330,000 in net income. Net profit margin of -121.28%.

Income Overview

Revenue
$27,482,000
Net Income
-$33,330,000
Net Profit Margin
-121.28%
EPS
-$0.69
Unit: Dollar
Revenue Breakdown
    • Jelmyto
    • Zusduri

Unit: Dollar
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Revenue
27,482,000 24,215,000 20,254,000 21,673,000
Cost of revenue
3,278,000 3,550,000 2,330,000 2,099,500
Gross profit
24,204,000 20,665,000 17,924,000 19,573,500
Research and development expenses
14,008,000 18,914,000 19,871,000 15,194,000
Selling, general and administrative expenses
37,582,000 43,199,000 34,967,000 31,078,500
Operating loss
-27,386,000 -41,448,000 -36,914,000 -26,699,000
Financing on prepaid forward obligation
4,621,000 4,644,000 4,583,000 5,861,500
Interest expense on long-term debt
3,373,000 4,132,000 4,068,000 3,169,500
Interest and other income, net
979,000 1,299,000 2,114,000 2,182,500
Loss before income taxes
-34,401,000 -48,925,000 -43,451,000 -33,547,500
Income tax benefit (expense)
-1,054,000 1,015,000 392,000 1,351,500
Net loss
-33,347,000 -49,940,000 -43,843,000 -34,899,000
Unrealized income (loss) on investments
17,000 -8,000 -42,000 -114,500
Comprehensive loss
-33,330,000 -49,948,000 -43,885,000 -35,013,500
Basic and diluted loss per ordinary share (in dollars per share)
-0.69 -1.05 -0.92 -0.75
Weighted-average number of ordinary shares (in shares)
48,057,386 47,739,816 47,422,119 -18,522,707.5
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$33,330,000 Unrealized income (loss) oninvestments$17,000 Net loss-$33,347,000 Income tax benefit(expense)-$1,054,000 Zusduri$1,779,000 Jelmyto$25,703,000 Loss before incometaxes-$34,401,000 Interest and otherincome, net$979,000 Revenue$27,482,000 Interest expense onlong-term debt$3,373,000 Financing on prepaidforward obligation$4,621,000 Operating loss-$27,386,000 Gross profit$24,204,000 Cost of revenue$3,278,000 Selling, general andadministrative expenses$37,582,000 Research and developmentexpenses$14,008,000

UroGen Pharma Ltd. (URGN)

UroGen Pharma Ltd. (URGN)